Figure 4.

Significance of EGLN2, EGLN3, and hydroxyproline expression in pancreatic cancer. Low levels of EGLN2 or EGLN3 mRNA expression were found in 49% and 64% of the patients, respectively (A). There was a significant positive correlation between EGLN2 mRNA expression and EGLN3 mRNA expression (B). Decreased EGLN2 expression was significantly associated with reduced disease-free survival and overall survival in (C). Decreased EGLN3 expression was significantly correlated with decreased disease-free survival and overall survival in (D). High expression of hydroxyproline was associated with early emergence of early distant recurrence (E).